Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment - PubMed (original) (raw)
Randomized Controlled Trial
. 2013 Jun 4;110(23):9523-8.
doi: 10.1073/pnas.1301816110. Epub 2013 May 20.
Affiliations
- PMID: 23690582
- PMCID: PMC3677457
- DOI: 10.1073/pnas.1301816110
Randomized Controlled Trial
Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment
Gwenaëlle Douaud et al. Proc Natl Acad Sci U S A. 2013.
Abstract
Is it possible to prevent atrophy of key brain regions related to cognitive decline and Alzheimer's disease (AD)? One approach is to modify nongenetic risk factors, for instance by lowering elevated plasma homocysteine using B vitamins. In an initial, randomized controlled study on elderly subjects with increased dementia risk (mild cognitive impairment according to 2004 Petersen criteria), we showed that high-dose B-vitamin treatment (folic acid 0.8 mg, vitamin B6 20 mg, vitamin B12 0.5 mg) slowed shrinkage of the whole brain volume over 2 y. Here, we go further by demonstrating that B-vitamin treatment reduces, by as much as seven fold, the cerebral atrophy in those gray matter (GM) regions specifically vulnerable to the AD process, including the medial temporal lobe. In the placebo group, higher homocysteine levels at baseline are associated with faster GM atrophy, but this deleterious effect is largely prevented by B-vitamin treatment. We additionally show that the beneficial effect of B vitamins is confined to participants with high homocysteine (above the median, 11 µmol/L) and that, in these participants, a causal Bayesian network analysis indicates the following chain of events: B vitamins lower homocysteine, which directly leads to a decrease in GM atrophy, thereby slowing cognitive decline. Our results show that B-vitamin supplementation can slow the atrophy of specific brain regions that are a key component of the AD process and that are associated with cognitive decline. Further B-vitamin supplementation trials focusing on elderly subjets with high homocysteine levels are warranted to see if progression to dementia can be prevented.
Keywords: causal modeling; clinical trial; degeneration; hippocampus; structural neuroimaging.
Conflict of interest statement
Conflict of interest statement: A.D.S. is named as inventor on three patents held by the University of Oxford on the use of B vitamins to treat Alzheimer’s disease or mild cognitive impairment (US6008221, US6127370, and PCT/GB2010/051557); H.R. is named as inventor on Patent PCT/GB2010/051557. Under the University of Oxford’s rules, they could benefit financially if the patents are exploited.
Figures
Fig. 1.
Regional loss of GM volume in placebo and B-vitamin groups. Placebo- and B-vitamin–treated groups showed significant reduction of GM volume over the 2-y period in similar regions (in yellow, P < 0.001 FWE-corrected for multiple comparisons, overlaid onto the average of all 156 GM volume images; Montreal Neurological Institute (MNI) coordinates in mm: x = −12, y = 4, z = −18). The extent and significance of volume loss appeared markedly greater in the placebo group compared with the B-vitamin group and is confirmed by direct statistical comparison (text and Fig. 2).
Fig. 2.
B-vitamin treatment significantly reduces regional loss of GM (P < 0.05 FWE-corrected). (A) Brain regions in blue demonstrate where B-vitamin treatment significantly reduces GM loss over the 2-y period (x = 26 and −8, y = −34 and −52, z = 0 and −16). All blue areas correspond to regions of significant loss in placebo and known to be vulnerable in AD (Fig. 1). (B) Percentage of GM loss for the 156 participants over the 2-y period, averaged across those brain regions that showed significant effect of B vitamins: placebo group (red triangles) had an average loss of 3.7% (±3.7), whereas the B-vitamin group (green circles) showed a loss of 0.5% (±2.9).
Fig. 3.
B-vitamin treatment is only effective in participants with higher tHcy levels (P < 0.05 FWE-corrected). (_A_) Brain regions in green demonstrate where B-vitamin treatment significantly reduces GM loss in participants with high tHcy levels (>11.06 μmol/L) at baseline (x = 26 and −8, y = −34 and −52, z = 0 and −16). (B) Percentage of GM loss for each of the 77 participants with high tHcy level: placebo group (n = 35) showed an average loss of 5.2% (±3.4) of GM volume over 2 y, whereas B-vitamin group (n =42) showed an average loss of 0.6% (±2.1).
Fig. 4.
Directed acyclic graph analysis of treatment and changes (“delta”) in B vitamins, tHcy, GM volume, and cognitive performance over the 2-y period. Of all possible edges (gray, A), we found that the optimal Bayesian network explaining our data (with a very good model fit, χ2 P = 0.64;
SI Methods
) identified nine statistical dependencies between variables (A, blue) and causality for each of these edges as presented in B (rearranged for clarity of display): treatment increases B vitamins' “delta” concentration, with B12 lowering tHcy “delta” concentration, which in turn slows grey matter atrophy (“gm”), which then delays cognitive decline over time (“sob” for CDR-SOB, “hvlt” for HVLT-R delayed recall, “flue\x{201d} for category fluency).
Similar articles
- Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial.
Smith AD, Smith SM, de Jager CA, Whitbread P, Johnston C, Agacinski G, Oulhaj A, Bradley KM, Jacoby R, Refsum H. Smith AD, et al. PLoS One. 2010 Sep 8;5(9):e12244. doi: 10.1371/journal.pone.0012244. PLoS One. 2010. PMID: 20838622 Free PMC article. Clinical Trial. - Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial.
de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD. de Jager CA, et al. Int J Geriatr Psychiatry. 2012 Jun;27(6):592-600. doi: 10.1002/gps.2758. Epub 2011 Jul 21. Int J Geriatr Psychiatry. 2012. PMID: 21780182 Clinical Trial. - Brain atrophy in cognitively impaired elderly: the importance of long-chain ω-3 fatty acids and B vitamin status in a randomized controlled trial.
Jernerén F, Elshorbagy AK, Oulhaj A, Smith SM, Refsum H, Smith AD. Jernerén F, et al. Am J Clin Nutr. 2015 Jul;102(1):215-21. doi: 10.3945/ajcn.114.103283. Epub 2015 Apr 15. Am J Clin Nutr. 2015. PMID: 25877495 Clinical Trial. - Efficacy of Vitamin B Supplementation on Cognition in Elderly Patients With Cognitive-Related Diseases.
Zhang DM, Ye JX, Mu JS, Cui XP. Zhang DM, et al. J Geriatr Psychiatry Neurol. 2017 Jan;30(1):50-59. doi: 10.1177/0891988716673466. Epub 2016 Oct 17. J Geriatr Psychiatry Neurol. 2017. PMID: 28248558 Review. - Folic acid with or without vitamin B12 for cognition and dementia.
Malouf M, Grimley EJ, Areosa SA. Malouf M, et al. Cochrane Database Syst Rev. 2003;(4):CD004514. doi: 10.1002/14651858.CD004514. Cochrane Database Syst Rev. 2003. PMID: 14584018 Updated. Review.
Cited by
- Unveiling the Therapeutic Potential of Folate-Dependent One-Carbon Metabolism in Cancer and Neurodegeneration.
Sobral AF, Cunha A, Silva V, Gil-Martins E, Silva R, Barbosa DJ. Sobral AF, et al. Int J Mol Sci. 2024 Aug 28;25(17):9339. doi: 10.3390/ijms25179339. Int J Mol Sci. 2024. PMID: 39273288 Free PMC article. Review. - Plasma homocysteine and longitudinal change in cognitive function among urban adults.
Beydoun MA, Beydoun HA, Georgescu MF, Maino Vieytes CA, Fanelli-Kuczmarski MT, Noren Hooten N, Evans MK, Zonderman AB. Beydoun MA, et al. J Affect Disord. 2024 Nov 1;364:65-79. doi: 10.1016/j.jad.2024.08.010. Epub 2024 Aug 10. J Affect Disord. 2024. PMID: 39134149 - Vitamin B6 ameliorates acute pancreatitis by suppressing the caspase3 signaling pathway.
Xu H, Yue H, Ge H, Wang F. Xu H, et al. BMC Gastroenterol. 2024 May 2;24(1):151. doi: 10.1186/s12876-024-03248-1. BMC Gastroenterol. 2024. PMID: 38698325 Free PMC article.
References
- Miller G. Alzheimer’s research. Stopping Alzheimer’s before it starts. Science. 2012;337(6096):790–792. - PubMed
- Clarke R, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55(11):1449–1455. - PubMed
- McCaddon A, Davies G, Hudson P, Tandy S, Cattell H. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry. 1998;13(4):235–239. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical